HomeAI · summaries
Storia in 2 fonti
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’ experimental CAR-T therapy. Novartis has paused immunology and neuroscience ...
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
- ·
qz.com
Novartis, Bristol Myers halt autoimmune CAR-T trials after deaths
Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a precaution
